AGL 37.01 Decreased By ▼ -0.99 (-2.61%)
AIRLINK 132.60 Decreased By ▼ -4.09 (-2.99%)
BOP 5.51 Increased By ▲ 0.09 (1.66%)
CNERGY 3.79 Decreased By ▼ -0.04 (-1.04%)
DCL 7.48 Decreased By ▼ -0.11 (-1.45%)
DFML 44.81 Decreased By ▼ -1.24 (-2.69%)
DGKC 81.20 Increased By ▲ 0.85 (1.06%)
FCCL 28.65 Increased By ▲ 0.62 (2.21%)
FFBL 54.75 Decreased By ▼ -0.46 (-0.83%)
FFL 8.55 Decreased By ▼ -0.03 (-0.35%)
HUBC 107.90 Decreased By ▼ -4.75 (-4.22%)
HUMNL 13.56 Increased By ▲ 1.23 (9.98%)
KEL 3.81 Decreased By ▼ -0.04 (-1.04%)
KOSM 7.04 Decreased By ▼ -1.03 (-12.76%)
MLCF 36.25 Increased By ▲ 1.14 (3.25%)
NBP 67.30 Increased By ▲ 1.30 (1.97%)
OGDC 169.49 Decreased By ▼ -1.67 (-0.98%)
PAEL 24.88 Decreased By ▼ -0.30 (-1.19%)
PIBTL 6.15 Decreased By ▼ -0.05 (-0.81%)
PPL 130.70 Decreased By ▼ -2.15 (-1.62%)
PRL 24.50 Increased By ▲ 0.10 (0.41%)
PTC 15.77 Increased By ▲ 1.25 (8.61%)
SEARL 57.80 Decreased By ▼ -1.15 (-1.95%)
TELE 6.99 Decreased By ▼ -0.10 (-1.41%)
TOMCL 34.73 Decreased By ▼ -0.27 (-0.77%)
TPLP 7.70 Decreased By ▼ -0.39 (-4.82%)
TREET 13.96 Decreased By ▼ -0.34 (-2.38%)
TRG 44.25 Decreased By ▼ -1.34 (-2.94%)
UNITY 25.15 Decreased By ▼ -0.84 (-3.23%)
WTL 1.18 Decreased By ▼ -0.02 (-1.67%)
BR100 9,082 Decreased By -1.8 (-0.02%)
BR30 27,380 Decreased By -251 (-0.91%)
KSE100 85,483 Increased By 30.2 (0.04%)
KSE30 27,160 Increased By 10.7 (0.04%)
World

China has fifth virus vaccine in human trial: official

"According to the plan, if all goes well, the above projects will complete the second phase of clinical trials in J
Published May 15, 2020
  • "According to the plan, if all goes well, the above projects will complete the second phase of clinical trials in July this year," Zeng said.
  • Zeng did not say when the trials, which must complete three phases for the drug to be approved for use, might be finished.
  • The drug must be administered to a group of volunteers and a placebo given to a control group in the same area where the virus is spreading to see if it works.

BEIJING: China has a fifth potential coronavirus vaccine in a human trial and more are on the way, a health official said Friday, as the world races to find a formula to stop the contagion in its tracks.

So far there have been no "major adverse reactions" reported among the 2,575 volunteers participating in the five phase-two tests, said Zeng Yixin, deputy director of the National Health Commission.

"According to the plan, if all goes well, the above projects will complete the second phase of clinical trials in July this year," Zeng said.

More vaccine candidates are in the pipeline and awaiting approval for human trials, he added.

China had previously said four human trials for possible vaccines were under way.

Zeng did not say when the trials, which must complete three phases for the drug to be approved for use, might be finished.

Scientists around the world are working at breakneck speed to develop a vaccine for COVID-19, the disease caused by the virus, which has killed more than 300,000 people and infected over 4.4 million.

But China's success in largely taming the outbreak could pose a hurdle for its vaccine developers when they reach the final stage of testing.

The drug must be administered to a group of volunteers and a placebo given to a control group in the same area where the virus is spreading to see if it works.

Beijing-based Sinovac Biotech, which developed one of the vaccines being tested, has told AFP that it is looking to carry out the final stage of its trial abroad because China does not have a large enough coronavirus cluster.

Experts say it will take at least 12 to 18 months to develop an effective vaccine, possibly even longer.

 

Comments

Comments are closed.